Search

Displaying results 9611 - 9620 of 10000 in total
  1. Drug

    REP8839

    go.drugbank.com/drugs/DB05224
    Experimental

    REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).

  2. Drug

    Parathyroid Hormone-Related Protein 1-36

    go.drugbank.com/drugs/DB16278
    Investigational

    Parathyroid Hormone-Related Protein 1-36 is under investigation in clinical trial NCT00853723 (Comparison Study of Pthrp and PTH to Treat Osteoporosis).

  3. Drug

    Etamicastat

    go.drugbank.com/drugs/DB15288
    Investigational

    Etamicastat is under investigation in clinical trial NCT02840565 (Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453).

  4. Drug

    Bevifimod

    go.drugbank.com/drugs/DB15301
    Investigational

    Bevifimod is under investigation in clinical trial NCT01749787 (Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis).

  5. Drug

    ALT-801

    go.drugbank.com/drugs/DB15386
    Investigational

    ALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia).

  6. Drug

    YS-ON-001

    go.drugbank.com/drugs/DB17291
    Investigational

    YS-ON-001 is a combination of an inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium).

  7. Drug

    Prifinium

    go.drugbank.com/drugs/DB13254
    Experimental

    Prifinium is an antimuscarinic agent with antispasmodic and antiemetic properties. It may be useful for the treatment of irritable bowel syndrome [A175027].

  8. Drug

    CTA30X UCAR-T

    go.drugbank.com/drugs/DB24819
    Investigational

    CTA30X UCAR-T is a biologic drug. CTA30X UCAR-T is under investigation in clinical trial NCT05015972 (UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies).

  9. Drug

    Ormeloxifene

    go.drugbank.com/drugs/DB13310
    Experimental

    activity in the uterus and breast. … [A251450,A251460] Ormeloxifene is marketed in India as a racemic mixture of the l- (levormeloxifene) and d-isomers (d-ormeloxifene) of _trans_-ormeloxifene.

  10. Drug

    Enlonstobart

    go.drugbank.com/drugs/DB21890
    Investigational

    [A274486] Enlonstobart is currently under investigation in clinical trial NCT06998771 (JSKN003 Combined Treatment of HER2-positive Gastric Cancer). … [A274486] It targets the programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours.